CELZ Key Statistics, Chart & Performance
The current stock price of CELZ is 1.96 USD. In the past month the price decreased by -11.51%. In the past year, price decreased by -19.67%.
CELZ Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About CELZ
Company Profile
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. The company is headquartered in Phoenix, Arizona and currently employs 4 full-time employees. The company went IPO on 2009-05-01. The firm conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
Company Info
CREATIVE MEDICAL TECHNOLOGY
211 E. Osborn Rd.
Phoenix ARIZONA US
Employees: 4
Phone: 14803992822
CREATIVE MEDICAL TECHNOLOGY / CELZ FAQ
What does CREATIVE MEDICAL TECHNOLOGY do?
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. The company is headquartered in Phoenix, Arizona and currently employs 4 full-time employees. The company went IPO on 2009-05-01. The firm conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
Can you provide the latest stock price for CREATIVE MEDICAL TECHNOLOGY?
The current stock price of CELZ is 1.96 USD. The price increased by 6.52% in the last trading session.
Does CREATIVE MEDICAL TECHNOLOGY pay dividends?
CELZ does not pay a dividend.
How is the ChartMill rating for CREATIVE MEDICAL TECHNOLOGY?
CELZ has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is CREATIVE MEDICAL TECHNOLOGY (CELZ) stock traded?
CELZ stock is listed on the Nasdaq exchange.
How is the market expecting CELZ stock to perform?
7 analysts have analysed CELZ and the average price target is 20.4 USD. This implies a price increase of 940.82% is expected in the next year compared to the current price of 1.96.
How is the valuation of CREATIVE MEDICAL TECHNOLOGY (CELZ) based on its PE ratio?
CREATIVE MEDICAL TECHNOLOGY (CELZ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.91).
CELZ Technical Analysis
CELZ Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CELZ. No worries on liquidiy or solvency for CELZ as it has an excellent financial health rating, but there are worries on the profitability.
CELZ Financial Highlights
Over the last trailing twelve months CELZ reported a non-GAAP Earnings per Share(EPS) of -2.91. The EPS increased by 23.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -101.85% | ||
| ROE | -106.61% | ||
| Debt/Equity | 0 |
CELZ Forecast & Estimates
7 analysts have analysed CELZ and the average price target is 20.4 USD. This implies a price increase of 940.82% is expected in the next year compared to the current price of 1.96.
For the next year, analysts expect an EPS growth of 43.91% and a revenue growth -62.5% for CELZ